Fludeoxyglucose (18F)

Generic Name
Fludeoxyglucose (18F)
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C6H11FO5
CAS Number
63503-12-8
Unique Ingredient Identifier
0Z5B2CJX4D
Background

Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-[18F]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). It is administered by intravenous injection.

Indication

The uptake of 18F-FDG by tissues is a marker for the tissue uptake of glucose, which in turn is closely correlated with certain types of tissue metabolism.
...

Associated Conditions
Cancer, Coronary Artery Disease (CAD), Epileptic seizure, Left Ventricular Dysfunction
Associated Therapies
-
Clinical Trials
Related News

The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients

Not Applicable
Conditions
Prostate Cancer
Interventions
Drug: 18F-PSMA-1007
Drug: 18F-FDG
First Posted Date
2024-12-09
Last Posted Date
2024-12-10
Lead Sponsor
Affiliated Hospital of Jiangnan University
Target Recruit Count
50
Registration Number
NCT06723665
Locations
🇨🇳

Affiated Hospital of Jiangnan University, Wuxi, Jiangsu, China

CD147 Targeting Peptide Probe for PET Imaging in Solid Tumors

Not yet recruiting
Conditions
Solid Tumor
Interventions
Drug: 18F-FDG
First Posted Date
2024-12-06
Last Posted Date
2024-12-06
Lead Sponsor
Peking University Cancer Hospital & Institute
Target Recruit Count
30
Registration Number
NCT06720298
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

Establishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular Imaging

Not Applicable
Not yet recruiting
Conditions
Breast Cancer
Interventions
Drug: 18F-FDG
First Posted Date
2024-12-04
Last Posted Date
2024-12-04
Lead Sponsor
Peking University Cancer Hospital & Institute
Target Recruit Count
60
Registration Number
NCT06715020

A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma

Early Phase 1
Not yet recruiting
Conditions
Multiple Myeloma and Malignant Plasma Cell Neoplasms
Interventions
Drug: 68Ga-BC1
Drug: 18F-FDG
First Posted Date
2024-12-04
Last Posted Date
2024-12-04
Lead Sponsor
Not specified
Target Recruit Count
50
Registration Number
NCT06717113

CD147 Targeting Nanobody Probe for PET Imaging in Solid Tumors

Recruiting
Conditions
Solid Tumor
Interventions
Drug: 18F-FDG
First Posted Date
2024-10-17
Last Posted Date
2024-12-05
Lead Sponsor
Hua Zhu
Target Recruit Count
30
Registration Number
NCT06646952
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

NeuroFLiPP: Parametric PET of Neuroinflammation in Fatty Liver Disease

Early Phase 1
Active, not recruiting
Conditions
Positron Emission Tomography
Interventions
Drug: 18F-DPA-714
Drug: 18F-FDG
First Posted Date
2024-06-12
Last Posted Date
2024-12-09
Lead Sponsor
University of California, Davis
Target Recruit Count
12
Registration Number
NCT06453915
Locations
🇺🇸

UC Davis EXPLORER Molecular Imaging Center, Sacramento, California, United States

Research on Early Diagnosis and Clinical Transformation of Nuclide Probe Based on Bioorthogonal-gastric Cancer Mucin Target Visualization

Not Applicable
Recruiting
Conditions
Solid Tumor
Interventions
Drug: 18F-FDG
First Posted Date
2024-05-28
Last Posted Date
2024-08-22
Lead Sponsor
Hua Zhu
Target Recruit Count
50
Registration Number
NCT06429891
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

PD-L1 Specific [68Ga]-Nb-1 Nanobody Probe for PET Imaging in Solid Tumors

Not Applicable
Recruiting
Conditions
Solid Tumor
Interventions
Drug: 18F-FDG
First Posted Date
2024-04-25
Last Posted Date
2024-11-28
Lead Sponsor
Hua Zhu
Target Recruit Count
50
Registration Number
NCT06383598
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

Single-tracer Multiparametric PET Imaging

Early Phase 1
Recruiting
Conditions
Healthy Subjects
Cardiovascular Disease
Interventions
Drug: 18F-FDG
Drug: 11C-butanol
First Posted Date
2023-08-28
Last Posted Date
2024-08-12
Lead Sponsor
University of California, Davis
Target Recruit Count
60
Registration Number
NCT06014515
Locations
🇺🇸

UC Davis EXPLORER Molecular Imaging Center, Sacramento, California, United States

68Ga-FAPI-04 PET Imaging in Early Response Evaluation of Rectal Cancer Patients Treated With Immunotherapy

Not Applicable
Recruiting
Conditions
Rectal Cancer
Interventions
Drug: 68Ga-FAPI-04
Drug: 18F-FDG
First Posted Date
2023-08-21
Last Posted Date
2023-08-21
Lead Sponsor
Wuhan Union Hospital, China
Target Recruit Count
20
Registration Number
NCT05999227
Locations
🇨🇳

China, Hubei Province, Wuhan, Hubei, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy